Victory Capital Management
INMB icon

Victory Capital Management’s INmune Bio INMB Stock Holding History

Victory Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,460
Closed -$4K – 2864
2020
Q1 		$4K Buy
+1,460
New +$6.59K ﹤0.01% 3530
2019
Q4 		– Sell
-843
Closed -$5K – 2929
2019
Q3 		$5K Buy
+843
New +$6.24K ﹤0.01% 3448

Other funds holding INMB

FAIM
Financial Advocates Investment Management Olympia, Washington $178M AUM 21.03% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CCM
Covington Capital Management Los Angeles, California $2.32B AUM 12.18% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
TPWA
TRUE Private Wealth Advisors Salem, Oregon $1.05B AUM 19.14% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Victory Capital Management's INMB Position: Q2 2020 in Review

Victory Capital Management sold out of INmune Bio (INMB) in Q2 2020, closing a stake of 1,460 shares — an estimated $4K sold.

Victory Capital Management first reported a position in INMB in Q3 2019 and held it in 2 quarters. The position peaked at $5K in Q3 2019. 16 funds tracked by Wall St. Rank hold INMB as of Q2 2020.

  • Victory Capital Management reported no remaining INmune Bio position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 1,460 INmune Bio shares in Q2 2020, an estimated $4K.
  • Victory Capital Management first reported a position in INmune Bio in Q3 2019 and held it in 2 quarters.
  • Victory Capital Management's INmune Bio position peaked at $5K in Q3 2019.
  • 16 funds tracked by Wall St. Rank held INmune Bio as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.